发明名称 Preventing or treating viral infection using an inhibitor of the LSD1 protein, a MAO inhibitor or an inhibitor of LSD1 and a MAO inhibitor
摘要 An embodiment of the invention provides a method of preventing or treating a viral infection of a host, comprising administering to the host an effective amount of an inhibitor of the protein LSD1 and/or a monoamine oxidase inhibitor. Another embodiment of the invention provides a method of preventing or treating reactivation of a virus after latency in a host, comprising administering to the host an effective amount of an inhibitor of the protein LSD1 and/or a monoamine oxidase inhibitor. Another embodiment of the invention provides a method of preventing or treating a viral infection in a mammal that has undergone, is undergoing, or will undergo an organ or tissue transplant, comprising administering to the mammal an effective amount of an inhibitor of the protein LSD1 and/or a monoamine oxidase inhibitor before, during, and/or after the organ or tissue transplant. The viral infection may be due to a herpesvirus, such as herpes simplex virus type 1 (HSV-1) or type 2 (HSV-2), varicella zoster virus (VZV), or cytomegalovirus (CMV). The viral infection may also be due to an adenovirus, including types 1-5.
申请公布号 US9499821(B2) 申请公布日期 2016.11.22
申请号 US201414543321 申请日期 2014.11.17
申请人 The United States of America, as represented by the Secretary, Department of Health and Human Services 发明人 Kristie Thomas;Liang Yu;Vogel Jodi
分类号 A61K48/00;C07H21/02;C07H21/04;A61K31/42;C12N15/113;A61K31/00;A61K31/137;A61K31/15 主分类号 A61K48/00
代理机构 Leydig, Voit & Mayer, Ltd. 代理人 Leydig, Voit & Mayer, Ltd.
主权项 1. A method of treating a herpesvirus or adenovirus viral infection of a host, comprising (a) detecting an immediate early (IE) gene expression level of the viral infection, (b) administering to the host an effective amount of an inhibitor of the protein LSD1, wherein the inhibitor is a non-monoamine oxidase inhibitor, and (c) detecting the IE gene expression level after administration of the inhibitor, wherein the viral infection is treated when the IE gene expression level is lower after administration of the inhibitor than before administration of the inhibitor.
地址 Washington DC US